Butyrylcholinesterase-injectable - Shire Pharmaceuticals

Drug Profile

Butyrylcholinesterase-injectable - Shire Pharmaceuticals

Alternative Names: BChE

Latest Information Update: 26 Jun 2002

Price : $50

At a glance

  • Originator Shire Pharmaceutical Development
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cocaine abuse

Most Recent Events

  • 26 Jul 2000 Butyrylcholinesterase is available for licensing (http://www.Shiregroup.com)
  • 24 Jul 2000 Preclinical development for Cocaine abuse in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top